Cancer Supportive Care Drugs Market Analysis Report By Therapeutic Class (G-CSFs, Bisphosphonates, Antiemetics, Opioids, NSAIDs, ESAs), By Major Markets, Vendor Landscape, And Segment Forecasts, 2016 - 2022

Industry Insights

The global cancer supportive care drugs market size was valued at USD 20.7 billion in 2016. It is projected to exhibit a CAGR of 1.8% over the forecast period. Supportive care in cancer focuses on prevention and management of symptoms and side-effects associated with cancer and its treatment. Key side effects caused by cancer treatment include anemia, neutropenia, nausea and vomiting, pain, and bone metastasis.

According to estimates from the International Agency for Research on Cancer (IARC), 12.7 million people are diagnosed with cancer and 7.6 million deaths are recorded every year. Lung and breast cancers are the most prominent cancer types with the highest demand for supportive care drugs. Breast, prostate, and lung cancers are likely to remain the top cancers diagnosed by 2022.

China and India are among promising destinations for market expansion. Factors such as growing uptake of biosimilar, beneficial healthcare reforms, and low-cost base are providing a fillip to the market in these two countries.

Several unmet needs remain in the cancer supportive care segment. Current treatment approaches provide only symptomatic relief. Effective analgesic drugs with lower risk of tolerance and abuse remain a key area of unmet need in this market.

Therapeutic Class Insights

The major drug classes involved in cancer supportive care include G-CSFs for treatment of neutropenia (CIN), ESAs for Anemia (CIA), antiemetics for nausea and vomiting (CINV), bisphosphonates for cancer induced bone diseases, and opioids and NSAIDs for treatment of cancer pain. Among these therapeutic classes, granulocyte stimulating factors (G-CSFs) such as Amgen’s Neupogen and Neulasta accounted for the largest market share in 2016 followed by opioids. The report highlights brands prescribed in cancer supportive care such as Amgen’s Neupogen, Neulasta, Epogen and Xgeva, Merck’s Emend, Roche’s NeoRecormon, Helsinn’s Aloxi, Heron’s Sustol, and Cinvanti among others.

The share for G-CSF drug class is expected to decline through the forecast period due to key patent losses and less use of myelosuppressive chemotherapy. Class of G-CSFs and ESAs have seen most number of biosimilar products, which has enabled increased access to affordable care for patients. Anti-emetics drug class is anticipated to post healthy growth during the same period, owing to new product launches. Targeted therapies currently dominate the space and are estimated to grow during the forecast period. Factors such as increasing use of immuno-oncology agents are poised to restrain the growth of the cancer supportive care drugs market over the coming years.

Pipeline Insights

Currently more than 10 products are undergoing clinical trials for treatment of various side-effects of cancer therapy. Some of the drugs are poised to aim at new molecular targets for treating side-effects in the cancer supportive care segment. Several market players are projected to work towards addressing unmet market needs, identifying new targets, and consequentially develop stronger drug pipelines.

As per the findings of the report, leading pipeline drugs such as Tanezumab and Rolontis are likely to be launched during the forecast period. Results from clinical trials of these drugs reported positive primary and secondary endpoint data. These drugs utilize improved drug delivery technologies to optimize efficacy and lower adverse side-effects.

Country Insights

By country, the market was dominated by the U.S. with more than 40.0% share in 2016. While the number of biosimilars launched in the U.S. is low, biosimilar penetration is anticipated to increase owing to twice the average price of biologics as compared to the rest of the world.

Japan has witnessed significant uptake of biosimilars over the past few years. Rising incidence of cancer along with large number of side-effects associated with cancer treatment is one of the key factors anticipated to stimulate the growth of the market in the country. Growing uptake of biosimilars, surging expenditure on healthcare, and availability of effective treatment methods, including target specific and tailored treatments are also benefiting the market in Japan.

Cancer Supportive Care Drugs Market Share Insights

Some of the players operating in this market are Amgen, Johnson & Johnson, Merck, Roche, Helsinn Healthcare, Heron Pharma, and Tesaro. Approval of Sustol and Cinvanti are expected to create significant market opportunity for Heron Pharma during the forecast period. The company also has a Phase III product candidate indicated for cancer pain.

Patent expirations and rising biosimilar competition have impacted several companies, most notably Amgen and Roche. Sandoz, Hospira, Teva Pharmaceuticals, 3SBio, and BioSidus are some of the major players in the biosimilar erythropoietin drugs market.

Report Scope

Segments Covered in the Report

This report forecasts revenue growth of the market at global & country levels and provides an analysis of industry trends in each of the sub-segments from 2016 to 2022. For the purpose of this report, Grand View Research has segmented the global cancer supportive care drugs market report on the basis of therapeutic class and country:

• Therapeutic Class Outlook (Revenue, USD Million, 2016 - 2022)

  • G-CSFs (Granulocyte-colony Stimulating Factors)

  • ESAs (Erythropoiesis Stimulating Agents)

  • Anti-emetics

  • Bisphosphonates

  • Opioids

  • NSAIDs

• Country Outlook (Revenue, USD Million, 2016 - 2022)

  • U.S.

  • U.K.

  • France

  • Germany

  • Italy

  • Spain

  • Japan